Paul Brousse Hospital Reports Findings in Personalized Medicine (Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant che motherapy in patients with pancreatic ductal adenocarcinoma)

扫码查看

原文链接

NETL
NSTL

外文摘要：By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News – New research on Drugs and Therapies - Personalized Medicine is the subject of a report. According to news reporting ou t of Villejuif, France, by NewsRx editors, research stated, “After surgical rese ction of pancreatic ductal adenocarcinoma (PDAC), patients are predominantly tre ated with adjuvant chemotherapy, commonly consisting of gemcitabine-based regime ns or the modified FOLFIRINOX regimen (mFFX). While mFFX has been shown to be mo re effective than gemcitabine-based regimens, it is also associated with higher toxicity.”

外文关键词：

VillejuifFranceEuropeAdenocarcinom aAdjuvant ChemotherapyAntimetabolitesAntineoplasticsAntiviralsCancerChemotherapyClinical Trials and StudiesCombined Modality TherapyCyborgsD rugs and TherapiesEmerging TechnologiesGastroenterologyGemcitabine TherapyHealth and MedicineImmunosuppressive AgentsMachine LearningOncologyPan creasPersonalized MedicinePersonalized TherapyPharmaceuticalsPre-Trial R esearchRadiation-Sensitizing Agents

出版年：

2024

Robotics & Machine Learning Daily News

ISSN：

年,卷(期)：2024.(Jul.4)